News

Crum & Forster's New Award Recognizes Innovative Underwriting

Crum & Forster's New Award Recognizes Innovative Underwriting

Crum & Forster Receives Prestigious Award

The recognition of excellence in the insurance sector has once again been exemplified by Crum & Forster's Surplus & Specialty (S&S) Division. This division has been honored with the 2025 Datos Insights Insurance Technology Impact Award for their innovative Surplus & Specialty Underwriting Platform, known as S&S UP. This modern platform represents a significant transformation in the underwriting processes within the organization.

Celebrating Innovation in Insurance

Datos Insights annually acknowledges the remarkable achievements of financial institutions that leverage cutting-edge technology to redefine industry standards. Their Impact Awards program serves as a beacon for innovations that revolutionize financial services and set new benchmarks for excellence.

Key Transformations in Underwriting

Since its implementation in early 2024, S&S UP has dramatically revolutionized workflows and automated many manual tasks. The integration of advanced in-house technologies, including generative AI and Optical Character Recognition, has drastically enhanced the efficiency of the underwriting process.

Improving Efficiency and Accuracy

As Bryan Brizzi, the Chief Digital Officer of S&S, stated, this award is a testament to the extraordinary collaboration between their technology and underwriting teams. Their combined efforts have not only reinvented operations but also led to a 35% reduction in quote turnaround time, improved data accuracy, and empowered underwriters to manage their portfolios with greater efficiency.

About Crum & Forster

Crum & Forster is a distinguished property, casualty, and accident & health insurer that provides specialty insurance products through both admitted and surplus lines insurance companies. With roots dating back to 1822, Crum & Forster stands as one of the oldest insurance firms in the U.S. and operates through a robust network of independent agents, brokers, and wholesalers.

A Legacy of Excellence

In the year prior, C&F reported an impressive $5.7 billion in gross written premiums and has consistently received an "A+" Superior rating from AM Best, underpinning their reliability in the insurance market. This legacy of excellence continues as they pave the way for future innovations.

Engaging with Crum & Forster

For more insights and updates, individuals are encouraged to connect with Crum & Forster on platforms such as LinkedIn, X, and Instagram. Engaging with their social media allows clients and interested parties to stay connected with the latest advancements and offerings from this historic company.

The Future of Insurance Technology

As industry standards evolve, Crum & Forster remains at the forefront, utilizing technology not just as an upgrade but as a foundation for a cultural shift within the organization. Their focus on innovation is motivated by the desire to enhance client outcomes and drive better business practices across the board.

Frequently Asked Questions

What is the award that Crum & Forster won?

Crum & Forster's Surplus & Specialty Division won the 2025 Datos Insights Insurance Technology Impact Award.

What does the S&S UP platform do?

The S&S UP platform streamlines workflows, automates manual processes, and integrates generative AI for improved underwriting efficiency.

How has the S&S UP platform impacted turnaround times?

The platform has achieved a 35% reduction in quote turnaround time, significantly enhancing efficiency for the underwriting team.

How long has Crum & Forster been in the insurance business?

Crum & Forster has been operating since 1822, making it one of the oldest insurance companies in the United States.

How can clients stay updated with Crum & Forster's news?

Clients can follow Crum & Forster on LinkedIn, X, and Instagram for updates and insights regarding their services and innovations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 13

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 8

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 10

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 6

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 11

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 13

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Credit Card Interest Rates and How to Manage Them

Updated Category News Views 352

Understanding Credit Card Interest Rates Recently, the average credit card interest rate has climbed to 22.63%, a notable rise from the previous average of 16.98%. The interest rate you face can vary widely based on the type of credit card and your individual credit profile. By understanding how credit card annual percentage rates (APR) work, you can potentially reduce...

Continue Reading
Hexaware Reports Strong Q3CY25 Performance with Revenue Rise

Updated Category News Views 183

Hexaware Technologies Financial Results Overview Hexaware Technologies (NSE: HEXT) has showcased impressive performance for the third quarter of calendar year 2025, with total revenue reaching USD 394.8 million. This figure marks a noteworthy increase of 5.5% year-over-year, showcasing the company's resilience and ability to navigate market challenges effectively....

Continue Reading
Alm. Brand A/S Reports Progress in Share Buybacks for 2024

Updated Category News Views 102

Overview of Alm. Brand A/S Share Buy-Back Program Alm. Brand A/S has kicked off an ambitious share buy-back program, looking to acquire shares totaling up to DKK 150 million. This initiative was officially announced earlier, providing insight into the year's financial strategy. Recent Transactions Under the Program During the week starting 9 September 2024 and ending on...

Continue Reading
NRx Pharmaceuticals Adjusts Release Date for Q2 Financials

Updated Category News Views 158

NRx Pharmaceuticals Announces Rescheduled Q2 2025 Financial Results Release NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) recently made an exciting announcement regarding the release of its second quarter 2025 financial results. The company has decided to delay the publication of these results to ensure a more comprehensive presentation for its stakeholders. This update comes...

Continue Reading
Top 5 Stocks to Watch for a Market Pullback Soon

Updated Category News Views 216

Understanding Market Pullbacks As major U.S. stock indices reached unprecedented levels recently, the optimism surrounding potential Federal Reserve rate cuts has driven prices higher. However, the surge seems excessive given the realistically anticipated modest decrease in rates. This opens a window for investors to reassess their portfolios, particularly those holdings...

Continue Reading